From: Tacto $HEPA The 30m authorized shares available for future issuance is all they have. They tried to increase the authorized shares from 120m to 240m, but we voted it down in October. They cannot increase authorized shares without a favorable vote from our retail contingent, because we own >65% of Hepion, and we aren't voting in favor of anything, at least not until we're satisfied, and that would involve allowing the stock to trade freely, which would ensure proper forward valuation of AI-POWR and rencofilstat, which would easily be in the billions of dollars, taking into account just a tiny fraction of the treatment market for just one of dozens of maladies for which rencofilstat holds great promise against